Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsGlobeNewsWire • Wednesday
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesGlobeNewsWire • 09/04/24
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerGlobeNewsWire • 08/19/24
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/24
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamAccesswire • 07/24/24
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyGlobeNewsWire • 07/24/24
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingGlobeNewsWire • 05/28/24
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation TargetAccesswire • 05/20/24
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings UpdateAccesswire • 05/14/24
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global ConferenceAccesswire • 05/06/24
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual MeetingAccesswire • 03/19/24
Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified ObjectiveAccesswire • 03/11/24
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy VolunteersAccesswire • 02/29/24
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings UpdateAccesswire • 02/14/24
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor ImmunotherapyAccesswire • 12/21/23
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public OfferingAccesswire • 10/25/23
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingAccesswire • 10/17/23
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB TechnologyAccesswire • 09/20/23